{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:42:50Z","timestamp":1787236970753,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T00:00:00Z","timestamp":1480204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2017,1]]},"abstract":"Summary<\/jats:title>\n \n Background<\/jats:title>\n Vonoprazan is a new potassium\u2010competitive acid blocker for treatment of acid\u2010related diseases.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n \n To conduct two randomised\u2010controlled trials, to evaluate the non\u2010inferiority of vonoprazan vs. lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (\n GU<\/jats:styled-content>\n ) or duodenal ulcer (\n DU<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients aged \u226520 years with \u22651 endoscopically\u2010confirmed\n GU<\/jats:styled-content>\n or\n DU<\/jats:styled-content>\n (\u22655 mm white coating) were randomised 1:1 using double\u2010dummy blinding to receive lansoprazole (30 mg) or vonoprazan (20 mg) for 8 (\n GU<\/jats:styled-content>\n study) or 6 (\n DU<\/jats:styled-content>\n study) weeks. The primary endpoint was the proportion of patients with endoscopically confirmed healed\n GU<\/jats:styled-content>\n or\n DU<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n For\n GU<\/jats:styled-content>\n , 93.5% (216\/231) of vonoprazan\u2010treated patients and 93.8% (211\/225) of lansoprazole\u2010treated patients achieved healed\n GU<\/jats:styled-content>\n ; non\u2010inferiority of vonoprazan to lansoprazole was confirmed [difference = \u22120.3% (95%\n CI<\/jats:styled-content>\n \u22124.750, 4.208);\n P<\/jats:italic>\n = 0.0011]. For\n DU<\/jats:styled-content>\n , 95.5% (170\/178) of vonoprazan\u2010treated patients and 98.3% (177\/180) of lansoprazole\u2010treated patients achieved healed\n DU<\/jats:styled-content>\n ; non\u2010inferiority to lansoprazole was not confirmed [difference = \u22122.8% (95%\n CI<\/jats:styled-content>\n \u22126.400, 0.745);\n P<\/jats:italic>\n = 0.0654]. The incidences of treatment\u2010emergent adverse events were slightly lower for\n GU<\/jats:styled-content>\n and slightly higher for\n DU<\/jats:styled-content>\n with vonoprazan than with lansoprazole. There was one death (subarachnoid haemorrhage) in the vonoprazan group (\n DU<\/jats:styled-content>\n ). The possibility of a relationship between this unexpected patient death and the study drug could not be ruled out. In both studies, increases in serum gastrin levels were greater in vonoprazan\u2010treated vs. lansoprazole\u2010treated patients; levels returned to baseline after treatment in both groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Vonoprazan 20 mg has a similar tolerability profile to lansoprazole 30 mg and is non\u2010inferior with respect to\n GU<\/jats:styled-content>\n healing and has similar efficacy for\n DU<\/jats:styled-content>\n healing.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/apt.13876","type":"journal-article","created":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T20:22:43Z","timestamp":1480278163000},"page":"240-252","source":"Crossref","is-referenced-by-count":109,"title":["Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers \u2013 results from two phase 3, non\u2010inferiority randomised controlled trials"],"prefix":"10.1111","volume":"45","author":[{"given":"H.","family":"Miwa","sequence":"first","affiliation":[{"name":"Hyogo College of Medicine Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Uedo","sequence":"additional","affiliation":[{"name":"Osaka Medical Center for Cancer and Cardiovascular Diseases Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Watari","sequence":"additional","affiliation":[{"name":"Hyogo College of Medicine Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Mori","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Takanami","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Tatsumi","sequence":"additional","affiliation":[{"name":"Osaka University Graduate School of Medicine Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sakaki","sequence":"additional","affiliation":[{"name":"Foundation for Detection of Early Gastric Carcinoma Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60596-6"},{"key":"e_1_2_7_3_1","first-page":"1433","article-title":"Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients\u2013focus on esomeprazole","volume":"8","author":"Tang RS","year":"2013","journal-title":"Clin Interven Aging"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03960.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170274"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.185314"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903314546"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.120428"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.179556"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.02.009"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02214870"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-006-6056-4"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.490"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0536-9"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302084"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T13:58:39Z","timestamp":1694267919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,27]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/apt.13876"],"URL":"https:\/\/doi.org\/10.1111\/apt.13876","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,27]]}}}